SCHEMBL2865013

SCHEMBL2865013

N#Cc1ccc2[nH]nc(-c3cccc(C(F)(F)F)c3)c2c1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 9/20 0.57
PIM1 P11309 1/20 0.53
PDPK1 O15530 2/20 0.53
ITK Q08881 1/20 0.51
MAP2K4 P45985 3/20 0.50
MAPK1 P28482 2/20 0.50
MAPKAPK3 Q16644 2/20 0.50
MAPK6 Q16659 2/20 0.50
MAPKAPK2 P49137 1/20 0.50
CTSS P25774 1/20 0.45
TRPA1 O75762 2/20 0.44
SCN5A Q14524 1/20 0.44
SCN9A Q15858 1/20 0.44
TDO2 P48775 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864778 0.83 ITK (0.54) LRRK2ITKMAP2K4
SCHEMBL2859279 0.81 ITK (0.64) LRRK2ITK
SCHEMBL2466587 0.80 PIM1 (0.56) LRRK2PIM1PDPK1MAP2K4MAPK1
SCHEMBL2860003 0.80 ITK (0.54) LRRK2ITKMAPK1
SCHEMBL17829665 0.79 AURKA (0.60) LRRK2PIM1PDPK1MAP2K4MAPK1
SCHEMBL17829688 0.78 PDPK1 (0.57) LRRK2PIM1PDPK1MAP2K4MAPK1
SCHEMBL2868413 0.77 LRRK2 (0.58) LRRK2ITK
SCHEMBL699881 0.76 PIM1 (0.52) LRRK2PIM1PDPK1MAP2K4MAPK1
SCHEMBL2860093 0.76 MAP2K4 (0.71) LRRK2PIM1PDPK1MAP2K4MAPK1
SCHEMBL5373058 0.76 MAP2K4 (0.63) LRRK2PIM1ITKMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
CN-1300116-C 1H-indazole compounds EISAI CO LTD (JP) 2007-02-14 CN disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
CN-1512987-A Novel 1H-indazole compound ������������ʽ���� 2004-07-14 CN disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 LRRK2 282/4885PIM1 247/4885PDPK1 885/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 LRRK2 817/4885PIM1 194/4885PDPK1 1320/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 LRRK2 282/4885PIM1 247/4885PDPK1 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.